- Home
- ADVM vs GDL Comparison
ADVM vs GDL Comparison
Compare ADVM & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- GDL
- Stock Information
- Founded
- ADVM 2006
- GDL 2006
- Country
- ADVM United States
- GDL United States
- Employees
- ADVM N/A
- GDL N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- GDL Investment Managers
- Sector
- ADVM Health Care
- GDL Finance
- Exchange
- ADVM Nasdaq
- GDL Nasdaq
- Market Cap
- ADVM 94.6M
- GDL 94.9M
- IPO Year
- ADVM 2014
- GDL N/A
- Fundamental
- Price
- ADVM $4.31
- GDL $8.51
- Analyst Decision
- ADVM Buy
- GDL
- Analyst Count
- ADVM 5
- GDL 0
- Target Price
- ADVM $16.60
- GDL N/A
- AVG Volume (30 Days)
- ADVM 1.0M
- GDL 11.2K
- Earning Date
- ADVM 11-07-2025
- GDL 01-01-0001
- Dividend Yield
- ADVM N/A
- GDL 6.02%
- EPS Growth
- ADVM N/A
- GDL N/A
- EPS
- ADVM N/A
- GDL N/A
- Revenue
- ADVM $1,000,000.00
- GDL N/A
- Revenue This Year
- ADVM $1,191.10
- GDL N/A
- Revenue Next Year
- ADVM N/A
- GDL N/A
- P/E Ratio
- ADVM N/A
- GDL N/A
- Revenue Growth
- ADVM N/A
- GDL N/A
- 52 Week Low
- ADVM $1.78
- GDL $7.65
- 52 Week High
- ADVM $8.18
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- ADVM 50.55
- GDL 51.31
- Support Level
- ADVM $4.18
- GDL $8.45
- Resistance Level
- ADVM $4.37
- GDL $8.53
- Average True Range (ATR)
- ADVM 0.20
- GDL 0.06
- MACD
- ADVM -0.03
- GDL 0.00
- Stochastic Oscillator
- ADVM 51.58
- GDL 79.41
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.